Search
for
Sort by
Research 30 of 224
- Recent Development in NSCLC Immunotherapies: Mechanisms, Advantages and Research Findings
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Therapeutic efficacy and safety of Kang-ai injection combined with platinum-based doublet chemotherapy in advanced NSCLC: A meta-analysis
- Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
- A prospective observational study on drug safety monitoring and Pharmacoeconomics in patients with locally advanced unresectable NSCLC in a tertiary care hospital
- Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
- Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
- Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer
- Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer
- The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
- A meta-analysis of the effectiveness and safety of Sintilimab combined with chemotherapy in the trea tment of advanced non-small cell lung cancer
- Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies
- [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
- Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
- Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer
- Proliferation, but Not Apoptosis, Is Associated with Distinct β-Catenin Expression Patterns in Non-Small-Cell Lung Carcinomas
- Three-Dimensional-Bioprinted Non-Small Cell Lung Cancer Models in a Mouse Phantom for Radiotherapy Research
- Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
- ES01.01 Chemotherapy is Strictly Additive to Immunotherapy
- Levels of sex steroids in lung tissues of patients with non‑small cell lung cancer after COVID‑19 of different severity